Study design, materials and methods
A retrospective analysis of a prospectively kept database was performed, of all patients receiving onabotulinumtoxinA injections at a tertiary centre. Cases were performed from 2015 to 2017, all under general anaesthesia. All patients were evaluated with pre-operative videourodynamic study and urethral pressure profilometry and all received 100U of treatment. All had three months of follow up.
Interpretation of results
After onabotulinumtoxinA, 6 were voiding, 2 were performing CISC, and 2 remained with an SPC. Median pre-op QMax improved from 8.5ml/s to 12.5ml/s, and mean post void residual volume decreased from 244mls to 94mls. 4 patients reported quality of life improvement after treatment, however 1 reported short lived benefit lasting less than 3 months. 2 patients went onto repeat treatments. There were no significant adverse events. 1 patient developed transient stress urinary incontinence after the injection.